Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Dermata Therapeutics ( (DRMA) ) is now available.
On December 23, 2025, Dermata Therapeutics entered into securities purchase and related agreements for a private placement of common stock, pre-funded warrants and Series C and D warrants, raising approximately $3.7 million in net proceeds (about $4.1 million gross) and creating the potential for roughly $8.3 million in additional gross proceeds if all warrants are exercised. Company insiders, including the CEO, CFO and members of management, participated on the same terms as outside investors, H.C. Wainwright & Co. acted as exclusive placement agent, and Dermata also agreed to reprice certain existing warrants, impose short-term limits on new equity issuance and variable-rate transactions, and register the resale of the new securities, with the fresh capital earmarked for general corporate purposes including research, pre-launch and launch activities for its new OTC acne kit, business development, licensing and working capital, reinforcing the company’s funding base as it advances its consumer-focused dermatology strategy.
The most recent analyst rating on (DRMA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics, based in San Diego, is a science-driven dermatology company that has recently pivoted to focus on over-the-counter pharmaceutical skin treatments. Its lead effort is a once-weekly OTC acne kit that combines an active ingredient from the OTC acne monograph with the company’s proprietary Spongilla technology, with an initial launch targeted for mid-2026 and additional dermatologic products planned thereafter.
Average Trading Volume: 548,260
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.91M
See more insights into DRMA stock on TipRanks’ Stock Analysis page.